Results 101 to 110 of about 1,093,493 (290)

Protective Role of Polydatin Against Vancomycin‐Induced Lung Toxicity via Oxidative Stress, Inflammation, Endoplasmic Reticulum Stress, Apoptosis, and Ferroptosis Pathways

Journal of Applied Toxicology, EarlyView.
ABSTRACT This study aimed to evaluate whether polydatin (Poly) could eliminate the harmful effects of vancomycin (VCM) on the lungs of rats. Rats were administered VCM (200 mg/kg) and Poly (50 mg/kg), both separately and in combination, for a duration of 7 days.
Serpil Aygörmez, Sefa Küçükler, Selim Çomaklı, Hasan Şimşek, Özge Kandemir, Fatih Mehmet Kandemir, Şaban Maraşlı   +6 more
wiley   +1 more source

Bisphenol A and Its Analogs: Toxicity Analysis in Mouse and Rat Liver—A Review

Journal of Applied Toxicology, EarlyView.
ABSTRACT Bisphenol A (BPA) and its analogs are widely recognized for their use in industry and plastic manufacturing. Consequently, humans and animals are continually exposed to various substances in their daily lives. This review evaluates the hepatic toxicity of BPA and its analogs in mice and rats, with particular emphasis on molecular mechanisms ...
Sevda Bagdatli, Muhammed Canik, Gizem Gencay, Nurbanu Zengin, Tarık Dinc, Nazan Deniz Yön   +5 more
wiley   +1 more source

Dual biologic therapy in inflammatory bowel disease, a retrospective cohort study of vedolizumab and anti‐tumor necrosis factor alpha therapy in children

Journal of Pediatric Gastroenterology and Nutrition, EarlyView.
Abstract Objectives Despite advances in pediatric inflammatory bowel disease (PIBD) with biologics, remission rates remain at 47%–60% with loss‐of‐response rates at 60%–68%. Evidence for efficacy of dual biologic therapy (DBT) with anti‐tumor necrosis factor alpha therapy (anti‐TNF‐α)‐ vedolizumab (VDZ) for children refractory to anti‐TNF‐α therapy is ...
Jonathan E. M. O'Donnell, Carlie Bolles, Claire R. Reilly, Manal Morgan, Christopher Burgess, Fariha Balouch, Peter J. Lewindon   +6 more
wiley   +1 more source

Subcutaneous immunotherapy in a patient taking ofatumumab for multiple sclerosis and upadacitinib for atopic dermatitis

Journal of Allergy and Clinical Immunology: Global
Allergen-specific immunotherapy has not been well-studied in the setting of increasingly common immune system-targeting medications. Subcutaneous immunotherapy may not be contraindicated in patients taking anti-CD20 mAbs antibodies and/or Janus kinase ...
Twan Sia, BA, Leeon Bacchus, BA, Stanley Liu, BS, John Leung, MD   +3 more
doaj   +1 more source

Hyperlipidaemic effect of Janus kinase inhibitors: a meta-analysis

, 2019
Introduction: Janus kinase (JAK) inhibitors are effective in treating rheumatoid arthritis. However, JAK is involved in lipid metabolism, so we investigated the association between JAK inhibitors and hyperlipidaemia.
Tsoi, MF, Cheung, TT, Cheung, BMY
core  

The safe and effective use of tofacitinib and ustekinumab combination therapy in infantile onset inflammatory bowel disease

JPGN Reports, EarlyView.
Abstract Infantile‐onset inflammatory bowel disease (IOIBD) is a rare and severe subset of very‐early‐onset IBD, often associated with immune dysregulation and poor response to conventional therapies. Data regarding the use of Janus kinase inhibitors (JAKI) in this population is limited.
Smridhi Mahajan, Christian Wysocki, Bhaskar Gurram   +2 more
wiley   +1 more source

Acneiform eruption associated with Janus kinase inhibitors in pediatric inflammatory bowel disease: Case series and clinical management guidance

JPGN Reports, EarlyView.
Abstract Janus kinase inhibitors (JAKi) are increasingly used for refractory inflammatory bowel disease (IBD) in pediatric patients but are associated with significant dermatologic adverse effects. Acneiform eruptions have been reported in up to 30% of adults, with a greater incidence suspected in adolescents.
Tina H. Tran, Daniel Park, Regina‐Celeste Ahmad, Malika Goel, Sofia Verstraete, Sabina Ali   +5 more
wiley   +1 more source

Effectiveness of  Janus kinase  inhibitors in  rheumatoid  arthritis:  systematic review  and  meta-analysis

Качественная клиническая практика
Aim.  To assess the efficacy profiles of different dosing regimens of tofacitinib, baricitinib, and upadacitinib — novel selective oral Janus activated kinase inhibitors, in rheumatoid arthritis (RA). Materials and methods.
A. E. Cheberda, D. Yu. Belousov
doaj   +1 more source

Revisiting Janus Kinase Inhibitors in Hospitalized COVID-19: Evidence for Baricitinib’s Superiority and the Absence of a Class Effect

Lei Gu,1,* Jing Lin,2,* Jian Yue,3,* Zeyi Liu,1 Jian-an Huang1 1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, People’s Republic of China; 2Department of ...
Liu Z, Gu L, Lin J, Huang JA, Yue J
core  

Paradoxical Alopecia Areata Induced by IL‐17 and IL‐23 Inhibitors: A Systematic Review

JEADV Clinical Practice, EarlyView.
This systematic review identifies consistent clinical patterns of alopecia areata associated with IL‐17 and IL‐23 inhibitors, most frequently involving secukinumab and ustekinumab. Disease severity varied widely, and management often required biologic discontinuation or therapeutic switching.
Isabella Kamholtz, Simonetta I. Gaumond, Joaquin J. Jimenez   +2 more
wiley   +1 more source